Skip to main content
Home > BioCentury on BioBusiness > Finance/Investment

Chronological Index of : Finance

 Current Issue
  • Sofinnova steps up

    Why Sofinnova Ventures upped the size of its tenth fund

    Ebb & Flow Ebb & Flow Sofinnova steps up Figure: Money Raised in 2016 Table: Earnings on deck With fewer crossover investors participating in its private biotech financings, Sofinnova Ventures has raised a new…

    Published on 10/24/2016
  • October spook

    Asking how low the biotech indices can go

    Ebb & Flow Ebb & Flow October spook Figure: Money Raised in 2016 Table: Earnings on deck The spooks have come out early this month thanks to a confluence of high-profile clinical and earnings blowups as well …

    Published on 10/17/2016
  • First North's big fish

    How Sweden's InDex plans to ramp its market cap post-IPO

    Ebb & Flow First North's big fish As the newest biotech on NASDAQ First North in Stockholm, InDex Pharmaceuticals Holding AB (SSE:INDEX) expects it will receive more attention from investors, as well as have less …

    Published on 10/17/2016
  • Figure: Money Raised in 2016

    October spook Money Raised in 2016 Last week, the biotech industry raised $90 million, bringing to $71.1 billion the total raised year-to-date. In 2015, a total of $108.9 billion was raised, including $54.8 …

    Published on 10/17/2016
  • Table: Earnings on deck

    October spook Earnings on deck At least five biotechs and pharmas are expected to report earnings this week. (A) Core EPS for the nine months ended Sept. 30, 2015; (B) Fiscal 2Q. Company Date Pre/post mkt …

    Published on 10/17/2016
  • Helsinn looks upstream

    Why Helsinn launched VC fund to invest in early stage companies

    Ebb & Flow Helsinn looks upstream Helsinn Investment Fund S.A. is primarily looking for financial returns, but the new early stage venture fund's investment remit also could lead to deals that would expand Helsinn …

    Published on 10/17/2016
  • Program or platform?

    Debating whether Alnylam's discontinued programs impact the rest of its pipeline

    Alnylam says two dropped programs won't read through to the rest of its pipeline, but data needed to reassure investors are a ways off.

    Published on 10/10/2016
  • Portfolio POC

    How CRT's Pioneer Fund got its first win by selling a Phase I asset to ProNAi

    Ebb & Flow Portfolio POC Cancer Research Technology Ltd.'s push to move molecules into the clinic rather than out-license them at very early stages of development has paid its first dividends. Late last month, the …

    Published on 10/10/2016
  • Figure: Money Raised in 2016

    M&Allergan Money Raised in 2016 Last week, the biotech industry raised $1,014 million, bringing to $70.8 billion the total raised year-to-date. In 2015, a total of $108.9 billion was raised, including $54.8 …

    Published on 10/10/2016
  • M&Allergan

    Totting up Allergan's available cash for M&A

    Ebb & Flow Ebb & Flow M&Allergan Figure: Money Raised in 2016 Even after a two-month stretch that has seen Allergan plc (NYSE:AGN) acquire five biotechs and in-license a pharma asset, the company's gas tank is …

    Published on 10/10/2016
  • Going big in Europe

    Why Arch's Carrick investment is the opposite of how it usually forms newcos

    Ebb & Flow Going big in Europe Arch Venture's biggest investment to date in Europe is also the complete opposite of how the firm normally starts biotech companies. Arch is co-leading a tranched $95 million series A…

    Published on 10/10/2016
  • Table: 4Q milestones

    ASH and others 4Q milestones Selected products with clinical or regulatory milestones expected in 4Q16. Source: BCIQ: BioCentury Online Intelligence Company Product Indication Event Milestone AcelRx …

    Published on 10/3/2016
  • Avalon's academic ADC

    Avalon-backed Fortis launches with ADC from UCSF for treatment-resistant cancers

    Ebb & Flow Avalon's academic ADC Avalon Ventures' latest academic deal has yielded a newco with an antibody-drug conjugate that will have Phase I data in two indications within the next three years. Last week, the…

    Published on 10/3/2016
  • Figure: Money Raised in 2016

    Better together Money Raised in 2016 Last week, the biotech industry raised $892 million, bringing to $69.7 billion the total raised year-to-date. In 2015, a total of $108.9 billion was raised, including $54.8 …

    Published on 10/3/2016
  • Dressed in black

    Biotech winners, losers in 3Q16

    For the first time in more than two years, all biotech market cap bands finished in the black.

    Published on 10/3/2016
  • Figure: London vs. Europe

    Dressed in black London vs. Europe The BioCentury Europe index rose 4% in 3Q16, edging it into positive territory for the year with a 0.4% gain after nine months. Fifteen of the 19 continental European companies …

    Published on 10/3/2016
  • Figure: Price-to-earnings: BT vs. RX

    Dressed in black Price-to-earnings: BT vs. RX Biotech's average P/E ended 3Q at 18.2, a four-year low. The P/E is down 26% from 2Q16 and 10% from 3Q15. The 3Q16 decline would have been steeper were it not for …

    Published on 10/3/2016
  • Figure: Results by market cap

    Dressed in black Results by market cap All market cap tiers gained in 3Q16, but still remain under water year to date. The biggest gains in 3Q16 came in the $200-$499 million tier, where gainers outnumbered …

    Published on 10/3/2016
  • Table: 3Q approvals

    Dressed in black 3Q approvals Selected 3Q approvals. Company Approval Amgen Inc. (NASDAQ:AMGN) FDA approves Amjevita adalimumab-atto, a biosimilar of autoimmune drug Humira adalimumab Aralez Pharmaceuticals …

    Published on 10/3/2016
  • Table: Index performance

    Dressed in black Index performance Index 3Q16 YTD BioCentury 100 15% -14% NASDAQ Biotechnology 12% -14% NYSE Arca Biotechnology 11% -12% NASDAQ Composite 10% 6% BioCentury London 5% 4% BioCentury…

    Published on 10/3/2016
  • Table: Restructuring watch

    Dressed in black Restructuring watch At least 12 companies reported workforce reductions in the third quarter compared to at least one in the same period last year. Table below is sorted by date ascending. All …

    Published on 10/3/2016
  • All in the family

    How Kleanthis Xanthopoulos obtained more family office firepower

    Ebb & Flow All in the family About a year after signing on to run family office Vendel Group, Kleanthis Xanthopoulos has decided he wants more firepower and is bringing additional offices into the fold. The …

    Published on 10/3/2016
  • ASH and others

    Investors' top names and milestones in 4Q16

    With ASH taking center stage, the fourth quarter is bubbling with milestones.

    Published on 10/3/2016
  • Guest Commentary: The generalist investor blame game

    Real data refute the long-held generalist hypothesis of life sci market moves

    Stifel's Peter Reikes and team provide data to refute the long-held generalist hypothesis of life sciences market moves.

    Published on 10/3/2016
  • Figure: Biotech fund flows

    Reasonable rally Biotech fund flows Biotech funds flows are down $4.8 billion year to date, and $432.5 million in 3Q16. Outflows for the quarter were tempered by inflow of $118 million in September. In the first …

    Published on 10/3/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993